Tetra Bio-Pharma (TBPMF) P/S Ratio
Tetra Bio-Pharma (TBPMF) has a price-to-sales ratio of 4.74x, placing it in the Premium range for cannabis stocks. The company has a market cap of $1.15B and TTM revenue of $1.24B. Revenue is declining 29.2% YoY.
P/S Ratio (TTM)
4.74x
EV/Revenue
2.87x
Market Cap
$1.15B
Revenue Growth
-29.2%
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $78.51 |
| Market Capitalization | $1.15B |
| TTM Revenue | $1.24B |
| Price-to-Sales (TTM) | 4.74x |
| EV/Revenue | 2.87x |
| Revenue Growth (YoY) | -29.2% |
| Gross Margin | 33.7% |
| Sector | Biotech |
| Exchange | OTC |
| Valuation Range | Premium |
Frequently Asked Questions
What is TBPMF's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides Tetra Bio-Pharma's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does TBPMF's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare Tetra Bio-Pharma to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is TBPMF overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if Tetra Bio-Pharma is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.